Article
Edwards Lifesciences Affirms FY2026 Adj EPS Guidance of $2.90-$3.05 vs $2.89 Est; Narrows FY2026 Sales Guidance from $6.400B-$6.800B to $6.553B-$6.674B vs $6.624B Est
Edwards Lifesciences (NYSE:EW) affirms FY2026 Adj EPS guidance from $2.90-$3.05 to $2.90-$3.05 vs $2.89 analyst estimate. Narrows FY2026 sales outlook from $6.400 billion-$6.800 billion to $6.553 billion-$6.674 billion vs $6.624 billion estimate.
Comments
- No comments yet. Be the first to comment!